U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C64H83N17O13
Molecular Weight 1298.4499
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAK-683

SMILES

CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](CC4=CC=C(O)C=C4)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(N)=O

InChI

InChIKey=BDPDXFSIFWZPCE-PHOVXGMNSA-N
InChI=1S/C64H83N17O13/c1-34(2)26-48(57(88)73-46(20-13-25-69-63(67)68-5)56(87)74-47(55(66)86)29-39-32-70-44-18-11-9-16-42(39)44)78-64(94)81-80-61(92)50(27-37-14-7-6-8-15-37)77-62(93)54(35(3)82)79-60(91)52(31-53(65)85)76-59(90)51(30-40-33-71-45-19-12-10-17-43(40)45)75-58(89)49(72-36(4)83)28-38-21-23-41(84)24-22-38/h6-12,14-19,21-24,32-35,46-52,54,70-71,82,84H,13,20,25-31H2,1-5H3,(H2,65,85)(H2,66,86)(H,72,83)(H,73,88)(H,74,87)(H,75,89)(H,76,90)(H,77,93)(H,79,91)(H,80,92)(H3,67,68,69)(H2,78,81,94)/t35-,46+,47+,48+,49-,50+,51-,52+,54+/m1/s1

HIDE SMILES / InChI

Molecular Formula C64H83N17O13
Molecular Weight 1298.4499
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 5
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue.
1999 Sep 10
A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization.
2000 Dec 29
Leukotrienes modulate cytokine release from dendritic cells.
2005 Dec
4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK.
2010 Jan 15
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:42:35 GMT 2023
Edited
by admin
on Sat Dec 16 11:42:35 GMT 2023
Record UNII
K56X3P8P9Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAK-683
Common Name English
TAK 683
Code English
(2S)-2-(((2R)-2-(((2R)-2-ACETAMIDO-3-(4-HYDROXYPHENYL)PROPANOYL)AMINO)-3-(1H-INDOL-3-YL)PROPANOYL)AMINO)-N-((1S,2R)-1-(((1S)-2-(2-(((1S)-1-(((1S)-1-(((1S)-2-AMINO-1-(1H-INDOL-3-YLMETHYL)-2-OXO-ETHYL)CARBAMOYL)-4-((N-METHYLCARBAMIMIDOYL)AMINO)BUTYL)CARBAM
Systematic Name English
L-TRYPTOPHANAMIDE, N-ACETYL-D-TYROSYL-D-TRYPTOPHYL-L-ASPARAGINYL-L-THREONYL-L-PHENYLALANYL-2-AZAGLYCYL-L-LEUCYL-N5-(IMINO(METHYLAMINO)METHYL)-L-ORNITHYL-
Systematic Name English
Code System Code Type Description
MANUFACTURER PRODUCT INFORMATION
TAK-683
Created by admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
PRIMARY MedKoo CAT NO: 202723, CAS NO: 872719-49-8Description: TAK-683 is an investigational peptide derivative of metastin that has been shown preclinically to be a potent metastin/GPR54 agonist both in vitro and in vivo. Administration of TAK-683 to male rats for 4 or 8 weeks has been shown to deplete GnRH in the hypothalamus and to reduce plasma FSH, LH and testosterone concentrations. The metastin analogue TAK-683 may be a promising candidate for further investigation in clinical trials in prostate cancer. A related metastin analogue, TAK-448, is also being evaluated in animal studies and in phase 1 clinical trials in prostate cancer (last updated: 7/13/2015).
PUBCHEM
49787129
Created by admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
PRIMARY
FDA UNII
K56X3P8P9Q
Created by admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
PRIMARY
CAS
872719-49-8
Created by admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Functional assay
EC50
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
BINDING
IC50
Related Record Type Details
ACTIVE MOIETY
Drug: TAK 683(Primary); Indication: Prostate cancer; Focus: Adverse reactions; Most Recent Events: 23 Aug 2012 New trial record, 18 Jul 2012 Results published in the British Journal of Clinical Pharmacology.
ACTIVE MOIETY
Originator: Takeda; Developer: Millennium; Class: Antineoplastic; Mechanism of Action: KISS1R protein agonist; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: Discontinued for Prostate cancer; Most Recent Events: 07 Apr 2009 Phase I development is ongoing in the UK
ACTIVE MOIETY
TAK-683 was well tolerated up to a dose of 2.0 mg day1 by continuous s.c. infusion for 14 days. Adverse events were similar between TAK-683 and placebo subjects at all dose levels. TAK-683 plasma concentrations generally increased in proportion to dose with single and continuous dosing, with steady-state concentrations achieved by day 2 of continuous dosing. TAK-683 at 2.0 mg day1 suppressed testosterone below castration level (<50 ng dl1) in four of five subjects by day 7 of continuous dosing. Luteinizing hormone and follicle stimulating hormone concentrations were suppressed with TAK-683 continuous dosing compared with placebo by up to 70 and 43%, respectively, but this was not consistently dose-dependent.